' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID


Gewähltes Keyword: Eslicarbazepine acetate

New anti-seizure medication for elderly epilepsy patients - a critical narrative review.
Rohracher, A; Kalss, G; Kuchukhidze, G; Neuray, C; Leitinger, M; Hofler, J; Kreidenhuber, R; Rossini, F; Volna, K; Mauritz, M; Poppert, N; Lattanzi, S; Brigo, F; Trinka, E
Expert Opin Pharmacother. 2021; 22(5):621-634
Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis.
Lattanzi, S; Zaccara, G; Giovannelli, F; Grillo, E; Nardone, R; Silvestrini, M; Trinka, E; Brigo, F;
Acta Neurol Scand. 2019; 139(1): 33-41.
Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Krauss, G; Biton, V; Harvey, JH; Elger, C; Trinka, E; Soares da Silva, P; Gama, H; Cheng, H; Grinnell, T; Blum, D;
Epilepsy Res. 2018; 139:1-8
Originalarbeiten (Zeitschrift)
Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
Trinka, E; Ben-Menachem, E; Kowacs, PA; Elger, C; Keller, B; Loffler, K; Rocha, JF; Soares-da-Silva, P
EPILEPSIA. 2018; 59(2): 479-491.
Originalarbeiten (Zeitschrift)
Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
Biton, V; Rogin, JB; Krauss, G; Abou-Khalil, B; Rocha, JF; Moreira, J; Gama, H; Trinka, E; Elger, CE; Cheng, HL; Grinnell, T; Blum, D
Epilepsy Behav. 2017; 72:127-134
Originalarbeiten (Zeitschrift)
Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
Elger, C; Koepp, M; Trinka, E; Villanueva, V; Chaves, J; Ben-Menachen, E; Kowacs, PA; Gil-Nagel, A; Moreira, J; Gama, H; Rocha, JF; Soares-da-Silva, P
CNS NEUROSCI THER. 2017; 23(12): 961-972.
Originalarbeiten (Zeitschrift)
Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study.
Schmid, E; Kuchukhidze, G; Kirschner, M; Leitinger, M; Höfler, J; Rohracher, A; Kalss, G; Wendling, AS; Steinhoff, BJ; Trinka, E;
Acta Neurol Scand. 2017; 135(4): 449-453.
Originalarbeiten (Zeitschrift)
Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies.
Shorvon, SD; Trinka, E; Steinhoff, BJ; Holtkamp, M; Villanueva, V; Peltola, J; Ben-Menachem, E;
J Neurol. 2017; 264(3): 42-431.
Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs.
Brigo, F; Bragazzi, NL; Nardone, R; Trinka, E;
Seizure. 2016; 42:29-37
A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy.
Brigo, F; Trinka, E; Bragazzi, NL; Nardone, R; Milan, A; Grillo, E;
Epilepsy Res. 2016; 127: 12-18.
Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I.
Grunze, H; Kotlik, E; Costa, R; Nunes, T; Falcão, A; Almeida, L; Soares-da-Silva, P;
J Affect Disord. 2015; 174:70-82
Originalarbeiten (Zeitschrift)
[Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate].
Steinhoff, BJ; Trinka, E; Wendling, AS;
Nervenarzt. 2011; 82(6): 764-767.
Originalarbeiten (Zeitschrift)